NCT06316531View on ClinicalTrials.gov

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

274

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

BL-M07D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

T-DM1

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

Unknown

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT06316531 - A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | Biotech Hunter | Biotech Hunter